Week in Medicine News and Research RSS Feed - Week in Medicine News and Research

EGFR–TKI response worse in NSCLC patients with rare EGFR mutations

EGFR–TKI response worse in NSCLC patients with rare EGFR mutations

In patients with non-small-cell lung cancer, rare epidermal growth factor receptor mutations are associated with a poorer response to EGFR–tyrosine kinase inhibitors compared with frequently occurring ones, according to a study published in Lung Cancer. [More]
Chemotherapy plus radiation improves survival in R1 NSCLC patients

Chemotherapy plus radiation improves survival in R1 NSCLC patients

US researchers have identified a survival benefit of postoperative combination chemotherapy and radiation treatment in patients with non-small-cell lung cancer who have microscopically positive surgical margins, regardless of pathological stage. [More]
Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Patients with anaplastic lymphoma kinase-rearranged non-small-cell lung cancer who have leptomeningeal metastases may benefit from treatment with the second-generation ALK inhibitor alectinib, a case series suggests. [More]
VATS lobectomy best for NSCLC patient short-term outcomes

VATS lobectomy best for NSCLC patient short-term outcomes

Video-assisted thoracoscopic surgery lobectomy offers better short-term outcomes for patients with early-stage non-small-cell lung cancer than open lobectomy, multi-institutional research confirms. [More]
Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Plasma EGFR mutation cfDNA predicts advanced lung cancer outcome

Monitoring plasma cell-free DNA levels of epidermal growth factor receptor mutations may indicate prognosis for patients with lung adenocarcinoma after EGFR–tyrosine kinase inhibitor therapy, research suggests. [More]
SRS fails to improve survival for NSCLC brain metastases patients

SRS fails to improve survival for NSCLC brain metastases patients

Phase III trial findings suggest that carrying out stereotactic radiosurgery before chemotherapy does not improve overall survival for non-small-cell lung cancer patients with asymptomatic brain metastases compared with chemotherapy alone. [More]

LUME-Lung 1 shows QoL, symptoms benefits

LUME-Lung 1 trial patients’ reports of symptoms and health-related quality of life support the use of second-line nintedanib for the treatment of advanced non-small-cell lung cancer. [More]
Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Amrubicin, carboplatin duo efficacious in thymic carcinoma, not invasive thymoma

Combination therapy with amrubicin and carboplatin is moderately effective in patients with advanced thymic carcinoma, a Japanese study finds, but invasive thymoma patients do not benefit from this regimen. [More]

Rare, complex EGFR mutations adversely affect EGFR–TKI treatment outcomes

Individuals with advanced non-small-cell lung cancer who have rare or complex epidermal growth factor receptor mutations have inferior outcomes in response to EGFR–tyrosine kinase inhibitor treatment compared with those with common mutations, research indicates. [More]
MET amplified in NSCLC irrespective of type, genetic background

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds. [More]
EGFR mutations, ALK translocations not mutually exclusive in NSCLC

EGFR mutations, ALK translocations not mutually exclusive in NSCLC

Researchers from the Republic of Korea have found that epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations can occur concomitantly in a proportion of patients with non-small-cell lung cancer. [More]
Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Single biopsy site may reveal all lung adenocarcinoma genetic mutations

Genetic sequencing of a single tumour site sample may be adequate for identifying cancer gene mutations in patients with lung andenocarcinoma, research published in Science suggests. [More]

Postop chemotherapy supported for stage III NSCLC

Study findings challenge the belief that preoperative chemotherapy is superior to postoperative chemotherapy for patients with clinical stage III non-small-cell lung cancer. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
Figitumumab development discontinued for non-adenocarcinoma NSCLC

Figitumumab development discontinued for non-adenocarcinoma NSCLC

Adding the novel insulin-like growth factor 1 receptor inhibitor figitumumab to the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib does not improve survival in patients with non-adenocarcinoma non-small-cell lung carcinoma, research shows. [More]
Postoperative recurrent disease affects NSCLC survival after gefitinib

Postoperative recurrent disease affects NSCLC survival after gefitinib

Patients with postoperative recurrent non-small-cell lung cancer harbouring epidermal growth factor receptor mutations have longer progression-free and overall survival with gefitinib treatment, than those with stage IV disease, Japanese researchers report. [More]
Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Overall survival in patients with metastatic lung cancer does not correlate with Kirsten rat sarcoma viral oncogene homologue mutation subtypes, US researchers report. [More]
Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Addition of S-1 to cisplatin plus radiotherapy ‘favourable’ in NSCLC

Research suggests that treatment with cisplatin plus S-1 together with thoracic radiotherapy is relatively efficacious and tolerable in patients with locally advanced non-small-cell lung cancer. [More]

First-line dacomitinib may improve advanced NSCLC survival

Preliminary research suggests that the second-generation tyrosine kinase inhibitor dacomitinib may improve progression-free survival in patients with advanced non-small-cell lung cancer with epidermal growth factor receptor mutations. [More]

Carboplatin and paclitaxel show promise for advanced thymic carcinoma

A multicentre, phase II study of carboplatin and paclitaxel in chemotherapy-naïve patients with advanced thymic carcinoma has shown that the treatment has promising efficacy compared with standard anthracycline-based chemotherapy. [More]